Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies
Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · 2783-2795
DOI: 10.1016/j.cgh.2026.02.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Remo Panaccione und 19 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Heterocyclic Compounds, 3-Ring, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND & AIMS: Upadacitinib (UPA) is an oral, reversible Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We assessed the long-term safety of UPA in both inflammatory bowel disease (IBD) entities. METHODS: Safety from 6 UC/CD trials assessed UPA 45 mg (UPA45) once daily (QD) induction, UPA 15 mg and 30 mg (UPA 15/30 QD) maintenance/long-term extension (LTE) doses, and rescue therapy (UPA30 QD). Adverse events (AEs) were reported as events per 100 patient-years (E/100 PY). RESULTS: Overall, 2118 patients received placebo (PBO; n = 725) or UPA45 (n = 1393) induction; 1419 received PBO (n = 468), UPA15 (n = 471), or UPA30 (n = 480) maintenance/LTE. During maintenance/LTE, UPA cumulative exposure was 5149.3 patient-years (n = 1910). Median treatment duration was 8.7 weeks (interquartile range [IQR], 8.0-12.0 weeks) for UPA45 induction; median maintenance/LTE treatment duration was 58.1 weeks (IQR, 30.4-164.0 weeks) for UPA15, and 130.9 weeks (IQR, 39.4-175.1 weeks) for UPA30. AE incidence was comparable between UPA and PBO during induction and maintenance/LTE; AEs leading to study drug discontinuation and serious or severe AEs were lower with UPA. During maintenance/LTE, rates (UPA15/30 vs PBO) of venous thromboembolic events (0.3/0.4 vs 0 E/100 PY), gastrointestinal perforations (0.4/
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
- Hospital Clinic Barcelona, IDIPABS, CIBERehd, Barcelona, Spain.
- Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, Vandœuvre-lès-Nancy, France.
- Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
- Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
- AZ Delta, Roeselare, Belgium.
Förderung
- AbbVie Inc
Zitieren
APA
Panaccione, R., Panés, J., Peyrin-Biroulet, L., Colombel, J. F., Lindsay, J. O., Baert, F., Atreya, R., Vermeire, S., Fujii, T., Dubcenco, E., Klaff, J., Duncan, B., Suravaram, S., Fish, I., Lacerda, A. P., Vladea, R., Ford, S., Shah, S., Anyanwu, S. I., & Rubin, D. T. (2026). Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clinical Gastroenterology and Hepatology, 24(10), 2783-2795. https://doi.org/10.1016/j.cgh.2026.02.018
Vancouver
Panaccione R, Panés J, Peyrin-Biroulet L, Colombel JF, Lindsay JO, Baert F, et al. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clinical Gastroenterology and Hepatology. 2026;24(10):2783-2795. doi:10.1016/j.cgh.2026.02.018
BibTeX
@article{Panaccione2026,
author = {Panaccione, Remo and Panés, Julián and Peyrin-Biroulet, Laurent and Colombel, Jean-Frédéric and Lindsay, James O and Baert, Filip and Atreya, Raja and Vermeire, Séverine and Fujii, Toshimitsu and Dubcenco, Elena and Klaff, Justin and Duncan, Benjamin and Suravaram, Smitha and Fish, Irina and Lacerda, Ana P and Vladea, Ramona and Ford, Sharanya and Shah, Saajan and Anyanwu, Samuel I and Rubin, David T},
title = {Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {10},
pages = {2783--2795},
doi = {10.1016/j.cgh.2026.02.018}
}
EUVIMED